Aprea Therapeutics is developing our lead program, APR-246, a novel reactivator of dysfunctional p53 that is positioned to be first-in-class. The safety, tolerability and activity of APR-246 have been established, including the potential for synergistic combination therapy with chemotherapy and immunotherapy agents.

We are currently enrolling a Phase II trial for APR-246 in platinum-sensitive and partially platinum-sensitive high-grade serous ovarian cancer (HGSOC). Phase Ib trials for platinum-resistant HGSOC, esophageal cancer, and myelodysplastic syndrome will be initiated in 2017. We are conducting preclinical evaluation of other cancer indications and additional Phase Ib studies are planned.

Inquiries for potential partnering opportunities should be directed to greg.korbel@aprea.com.